Jie Wang

机构：Chinese Academy of Medical Sciences & Peking Union Medical College

发表论文 3 篇 · 总被引 75 次 · h-index 3

代表论文

• Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial (2026 · The Lancet · 被引 25)
• Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study (2026 · CA A Cancer Journal for Clinicians · 被引 5)
• Osimertinib with/without chemotherapy in patients with persistent ctDNA EGFR mutant (EGFRm) NSCLC at 3 weeks after 1L osimertinib: A randomized phase II study (FLAME study). (2026 · Journal of Clinical Oncology · 被引 1)
• Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175] (2026 · Journal of Thoracic Oncology)